Home › Companies › Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. (GYRE) proxy voting records

How asset managers voted at Gyre Therapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• TickerGYRE
• CUSIP issuer number403783
• SEC CIK1124105

Recent shareholder votes

• June 10, 2026 annual meeting (2025-2026 proxy season): 5 items in Gyre Therapeutics, Inc.'s official results (Form 8-K, filed June 16, 2026); lowest support 99.4% of votes cast (Elect Director: David M. Epstein, Ph.D.). Full results and how funds voted.
• June 4, 2025 annual meeting (2024-2025 proxy season): 5 items in Gyre Therapeutics, Inc.'s official results (Form 8-K, filed June 6, 2025); lowest support 99.5% of votes cast (Elect Director: Gordon Carmichael, Ph.D.). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Explore Gyre Therapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.